Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microneedle Technologies for Drug Delivery: Innovations, Applications, and Commercial Challenges.

Micromachines·2026
Same author

Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches.

Antibodies (Basel, Switzerland)·2026
Same author

Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances Chemosensitivity.

Cancers·2025
Same author

STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies.

Biochimica et biophysica acta. Reviews on cancer·2025
Same author

Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Multiplatform Metabolomics to Understand the Imidacloprid-Induced Toxicity in <i>Drosophila</i>.

Chemical research in toxicology·2023

Related Experiment Video

Updated: Jan 13, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro Assessment.

Rameswari Chilamakuri1, Deepika Godugu1, Saurabh Agarwal1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA.

Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
PubMed
Summary

Targeting CXC chemokine receptor 2 (CXCR2) with SB225002 effectively inhibits neuroblastoma (NB) growth and spread. This CXCR2 inhibition offers a promising new therapeutic strategy for high-risk NB patients.

Keywords:
CXCR2IL-8SB225002neuroblastomapediatric cancer

More Related Videos

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

12.7K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

418

Related Experiment Videos

Last Updated: Jan 13, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

12.7K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

418

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • High-risk neuroblastoma (NB) presents significant challenges due to metastasis, drug resistance, and low survival rates.
  • Current treatments for NB are intensive and associated with significant toxicities.
  • CXC chemokine receptor 2 (CXCR2) is implicated in promoting NB progression and treatment resistance.

Purpose of the Study:

  • To investigate the prognostic significance of CXCR2 expression in NB patient samples.
  • To evaluate the anti-tumor effects of pharmacological CXCR2 inhibition using SB225002.
  • To elucidate the molecular mechanisms underlying CXCR2's role in NB pathogenesis.

Main Methods:

  • Analysis of transcriptomic data from 1464 primary NB patient samples.
  • In vitro assessment of SB225002's effects on NB cell lines (proliferation, apoptosis, cell cycle).
  • Utilized 3D spheroid models to mimic in vivo tumor microenvironments and assessed mechanistic signaling pathways.

Main Results:

  • High CXCR2 expression correlated inversely with overall survival in NB patients.
  • SB225002 significantly inhibited NB cell proliferation, colony formation, and induced apoptosis and cell cycle arrest.
  • SB225002 impaired spheroid formation and growth in 3D models, downregulating key oncogenic targets like GLIPR1 and AKT1.

Conclusions:

  • Pharmacological inhibition of CXCR2 with SB225002 demonstrates potent anti-tumor activity against neuroblastoma.
  • Targeting CXCR2 modulates critical oncogenic signaling networks involved in NB growth and tumorigenicity.
  • CXCR2-targeted therapies represent a promising therapeutic avenue for high-risk neuroblastoma.